This Billionaire’s Fund Returned 30% This Year; Here Are Some of His Top Stock Picks
Michael Hintze is the founder of multi-strategy asset management firm CQS Cayman. In 2016, Hintze's CQS Directional Opportunities fund posted a stunning 30% return.
Posts Tagged ‘Ariad Pharmaceuticals Inc. (ARIA)’
Five Stocks on the Move in the Wake of Trump’s Election Win
After opening rather calmly on the news that Donald Trump is now the President-elect, the markets are down slightly as investors remain cautious on the political changes ahead...
Mallinckrodt PLC (MNK) & Depomed Inc (DEPO) Helped Consonance Capital to Massive Q3 Returns
The majority of hedge funds and other top money managers tend to have a long-term focus when they make investments.
This Healthcare Fund Just Had A Huge Q3: Here’s How
The mainstream media likes taking shots at hedge funds because they are easy targets.
Ariad Pharmaceuticals, Inc. (ARIA)’s Brigatinib Granted Priority Review
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)'s lung cancer drug brigatinib has been accepted for review by the FDA.
Trending Stocks: Diplomat Pharmacy, Facebook, Ariad Pharmaceuticals, and More
Although the broader markets are still down/flat due in large part to Apple Inc.
Tidewater, Inovio, Ariad, and More: What is Going on With These Falling Stocks?
Although the broader markets are in the green today as a wave of M&A activity and a number of solid earnings reports have improved market sentiment, several stocks are not on ...
Here’s Why These Five Stocks Are in the Spotlight
While the second trading week of the fourth quarter is officially over, several major stocks are trending over the weekend, including Twitter Inc (NYSE:TWTR), salesforce.com, ...
Why Apple, Microsoft, Corning, Ariad, and More Are in the Spotlight
The markets are relatively quiet as the latest data shows that durable goods orders in the United States were relatively flat month-over-month in August.
Today’s Trending Stocks: Pioneer, Ariad, Hershey, and 2 More
Crude futures are in the red today as sentiment around the commodity cools off.
Why Mosaic, Vale, and Three Other Stocks Are in the Spotlight
Crude futures are well in the green this morning as the worry over a potential 'Brexit' diminishes.
Ariad Pharmaceuticals, Inc. (ARIA) To Seek Regulatory Clearance For Brigatinib In 3Q
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has said that it will file a new drug application (NDA) for its pipeline candidate brigatinib in 3Q2016.
Noteworthy Insider Trading Activity at These 5 Companies as Insider Buying Ratio Increases
Last week’s dollar volume of all insider purchases almost doubled week-over-week, whereas the volume of insider selling decreased quite meaningfully relative to the volume of...
Five Cheap Healthcare Stocks With Hedge Fund Support
When it comes to the risk-reward ratio, there are very few sectors which can match up to healthcare.
Ubben Sells More Shares of Motorola Solutions Inc. (MSI), Meister Cuts Stake in This REIT, Plus 2 Other Moves
Fresh data shows that 2015 was the year with the highest number of hedge fund closures since the financial crisis, as increased volatility in equity markets significantly impacted...
Five Cheap Healthcare Stocks Poised to Explode
Over the past few months the healthcare sector has undergone a roller coaster of a ride, especially in August and September when many investors got wary of the sector being overvalued...
Why Are These Stocks Among Today’s Losers?
This week's roller coaster is coming to and end with a bang, as U.S. stocks are deep in the red territory and the Dow is down by triple digits.
5 Healthcare Stocks Under $10 Ready To Pop
Investing in the healthcare sector can be tricky, especially if you're looking for high returns and want to invest in clinical-stage companies, which represent an above-average...
Hedge Funds Like Ariad Pharmaceuticals, Inc. (ARIA) Despite the Failed Deal
Less than a week after reports that Baxalta Inc (NYSE:BXLT) wanted to acquire Ariad Pharmaceuticals, Inc.
The Good, The Bad, And The Ugly: A Journey Into Jonathan Soros’ Top Small-Cap Picks
JS Capital Management is a New York-based hedge fund founded and led by Jonathan Soros.
Hedge Fund News: Alex Denner, Steven Tananbaum, Bill Ackman
Ariad Pharmaceuticals founder and CEO Harvey Berger is exiting the struggling cancer drug company in a settlement with Sarissa Capital, the activist hedge fund led by Alex Denner...
Ariad Pharmaceuticals, Inc. (ARIA), Amgen, Inc. (AMGN): How Sarissa Capital’s Top Picks Beat the Market
Headquartered in Connecticut, Sarissa Capital Management was founded by Alexander J. Denner in 2012. Prior to this, Mr.
Ariad Pharmaceuticals, Inc., Quest Diagnostics Inc, Amgen, Inc.: Sarissa Capital’s Top Stock Picks and New Moves
Alex Denner’s Sarissa Capital Management recently disclosed its stock picks for the fourth quarter of 2014 in a 13F Form filed with the U.S.
Townsquare Media Inc, Aegerion Pharmaceuticals, Inc.: Tricadia Capital Increases Stake; Sarissa Capital Enters New Position
Michael Barnes And Arif Inayatullah’s Tricadia Capital Management recently disclosed an increase to its position in Townsquare Media Inc (NYSE:TSQ) of 555,500 Class A Common...
Ariad Pharmaceuticals, Inc. (ARIA): Healthcare-focused Sarissa Capital Inches Up Its Stake to 6.87%
As a new filing with the Securities and Exchange Commission showed, Sarissa Capital Management, a fund led by Alex Denner, has picked up its position in Ariad Pharmaceuticals...
Activist Alex Denner’s Sarissa Capital Bets on Ariad Pharmaceuticals Inc (ARIA), Quest Diagnostics Inc (DGX) & Others
Alex Denner’s Sarissa Capital disclosed its holdings in its latest and first 13F filings.
Hedge Fund News: John Paulson, Marc Faber & Warren Buffett
Hedge funds held up better than global stocks last month, falling an average of 0.1 percent as equities slumped amid a selloff in emerging-market currencies and signs of weakness...
Former Icahn MD’s Sarissa Capital Discloses 6.2% of Ariad Pharmaceuticals
According to a new filing with the SEC, Sarissa Capital Management now holds around 11.5 million shares of Ariad Pharmaceuticals, Inc.
Santarus, Inc. (SNTS), Pharmacyclics, Inc. (PCYC), Ariad Pharmaceuticals, Inc. (ARIA): Should You Jump on This Biotech After Profit-Taking?
After a truly remarkable 20-month 650% gain, shares of Santarus, Inc. (NASDAQ:SNTS) have fallen by more than 20% since its all-time high in early August.
Ariad Pharmaceuticals, Inc. (ARIA), Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Does This Orphan Leukemia Treatment Have Blockbuster Potential?
When most biotech investors think of cancer treatments, they tend to think of large established players like Roche and Amgen.
Do Hedge Funds and Insiders Love Seattle Genetics, Inc. (SGEN)?
At the moment, there are a multitude of metrics shareholders can use to monitor stocks. A pair of the most useful are hedge fund and insider trading sentiment.
Incyte Corporation (INCY): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In the 21st century investor’s toolkit, there are many gauges shareholders can use to track their holdings.
Elan Corporation, plc (ADR) (ELN), Tibco Software Inc. (TIBX): What This 758% Gainer Has Been Buying
Today, let's look at investing giant Daniel Loeb, founder of the Third Point LLC hedge fund.
Santarus, Inc. (SNTS), Aegerion Pharmaceuticals, Inc. (AEGR), Ariad Pharmaceuticals, Inc. (ARIA): Did a Strong New Drug Make This Biotech Overvalued?
Santarus, Inc. (NASDAQ:SNTS) has risen over 300% in the past year partly based on sales optimism for ulcerative colitis drug Uceris, which launched in the first quarter.
This Metric Says You Are Smart to Sell Ariad Pharmaceuticals, Inc. (ARIA)
In the eyes of many investors, hedge funds are seen as overrated, old financial tools of a forgotten age.
Should You Avoid Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ)?
In today’s marketplace, there are a multitude of gauges market participants can use to analyze their holdings.
What Hedge Funds Think About Medivation Inc (MDVN)
In today’s marketplace, there are a multitude of methods shareholders can use to monitor the equity markets.
Real Estate News: Annaly Capital Management, Inc. (NLY) New CFO, American Capital Agency Corp. (AGNC)’s Put Options, American Capital Ltd. (ACAS) Percentage Change
Annaly Capital Management, Inc. (NYSE:NLY), a real estate investment trust based in New York, promoted Glenn A. Votek to chief financial officer. He succeeds Kathryn F.
Santarus, Inc. (SNTS), Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ): Three Earning Catalysts That Could Push This Biotech Even Higher
Santarus, Inc. (NASDAQ:SNTS) has traded higher by 250% over the last year, and much of those gains have been created after the company’s last two quarterly reports.
Onyx Pharmaceuticals, Inc. (ONXX), Pharmacyclics, Inc. (PCYC): Will This Biotech Acquisition Buzz Lead to More Buyouts?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is trading higher after rejecting a takeover bid.
Celldex Therapeutics, Inc. (CLDX) On The Rise
There are many biotech stocks that target cancer, but what is good about Celldex Therapeutics, Inc.
Galena Biopharma Inc (GALE): Should You Buy the Hype Surrounding This Product Launch?
While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with success.
Ariad Pharmaceuticals, Inc. (ARIA), VIVUS, Inc. (VVUS): Winning Biotech Investment Strategies and Their Potential Pitfalls
Investing in biotech companies isn't without its challenges, but it doesn't have to be a shot in the dark, either.
Aegerion Pharmaceuticals, Inc. (AEGR), Arena Pharmaceuticals, Inc. (ARNA): Investment Opportunities in Drug Launches
There are investment opportunities in every sector, but biotechs launching new drugs offer a unique investment opportunity to take advantage of hyper-growth as sales increase ...
Bristol Myers Squibb Co. (BMY), Ariad Pharmaceuticals, Inc. (ARIA): ASCO Investment Ideas
The American Society of Clinical Oncology annual meeting kicks off today.
Here is What Hedge Funds Think About Ariad Pharmaceuticals, Inc. (ARIA)
To the average investor, there are a multitude of indicators market participants can use to watch publicly traded companies.
Yahoo! Inc. (YHOO), Virgin Media Inc. (VMED): Here’s What This 758% Gainer Has Been Buying
Today, let's look at investing giant Daniel Loeb, founder of the Third Point LLC hedge fund.
MannKind Corporation (MNKD)’s Run to Glory
Shares of MannKind Corporation (NASDAQ:MNKD) have nearly tripled over the last year.
